Targeted Therapy

Antibody-drug conjugates (ADCs) are targeted cancer therapies that combine a monoclonal antibody with a potent chemotherapy drug, delivering treatment directly to cancer cells while sparing healthy tissue. Often called “smart bombs,” ADCs improve outcomes across several cancers. An ADC works in four steps: the antibody binds specifically to cancer cell proteins, the complex is internalized, […]

New first-line therapy has transformed treatment for BRAF V600E–mutated metastatic colorectal cancer (mCRC), an aggressive subtype with historically poor outcomes. FDA approval of the triple combination—encorafenib, cetuximab, and mFOLFOX6—marks a major breakthrough for these patients. The BREAKWATER trial demonstrated that this regimen doubled overall survival to 30.3 months compared with 15.1 months for standard therapy,

CAR T-cell therapy, initially successful in blood cancers, is showing promise in solid tumors like gastric and esophageal cancers. This therapy engineers a patient’s T-cells to recognize and attack cancer, but solid tumors present unique challenges. Tumor antigens can vary, making it hard to target cancer without affecting healthy tissue. The dense tumor microenvironment suppresses